Yongxiang Xia
Nanjing University of Chinese Medicine(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Nanjing Medical University(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cholangiocarcinoma and Gallbladder Cancer Studies, Hepatocellular Carcinoma Treatment and Prognosis, Pancreatic and Hepatic Oncology Research, Immune Cell Function and Interaction
Most-Cited Works
- → Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial(2023)431 cited
- → Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3(2011)301 cited
- → Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma(2015)216 cited
- → Biliary Tract Cancer at CT: A Radiomics-based Model to Predict Lymph Node Metastasis and Survival Outcomes(2018)201 cited
- → Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial(2022)198 cited
- → Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial(2020)